Latest Treatments of Parkinson's Disease Stories
Research and Markets (http://www.researchandmarkets.com/research/9a0ef4/cns_drug_discoveri) has announced the addition of the "CNS Drug Discoveries: Parkinson's Disease Chapter" report to their offering. This chapter of CNS Drug Discoveries focuses on the Parkinson's disease market.
Depomed, Inc. (NASDAQ:DEPO) announced today that it has been awarded a preclinical grant by The Michael J. Fox Foundation under the foundation's Therapeutics Development Initiative 2008 Program.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that results from the ADAGIO study will be presented at the 12th Congress of European Federation of Neurological Societies (EFNS) on August 26, 2008 in Madrid, Spain.
By PETER GOTT Dear Dr. Gott: I was diagnosed with Parkinson's disease in June 2005. I take Mirapex, which is prescribed, and co-enzyme Q10, which is not. I read somewhere that Q10 is a good over-the-counter for people with Parkinson's disease.
FDA APPROVES REQUIP(R) XL(TM), THE FIRST AND ONLY ORAL ONCE-DAILY NON-ERGOT DOPAMINE AGONIST FOR PARKINSON'S DISEASE Extended-Release Formulation Improved Symptoms in Patients Not Optimally Controlled with Levodopa and Reduced Patients'"Off" Time by Nearly Two Hours Per Day LONDON, UK, 16 June 2008 -- SkyePharma PLC (LSE: SKP) today announces that the United States Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE: GSK) Requip(R) XL(TM) (ropinirole extended-release...
CAMBRIDGE, Mass. and WINNERSH, U.K., May 8, 2007 (PRIME NEWSWIRE) -- Biogen Idec (Nasdaq:BIIB) and Vernalis plc (Nasdaq:VNLS) (LSE:VER) today announced the initiation of the Phase II program of BIIB014 (also known as V2006), an oral compound, for the treatment of Parkinson's disease.
NEW YORK (Reuters Health) - Genetically modified nerve 'progenitor' cells can be used as mini-pumps to deliver nerve growth factor to the brain, a new study in animals shows. The results suggest such an approach could be used to treat Parkinson's disease and other brain diseases in humans, Dr.
A class of drugs known as MAO-B inhibitors may be effective in improving motor symptoms in people with early Parkinsonâ€™s disease and may delay the need for treatment with other drugs, according to a new systematic review of current evidence.
NEW YORK (Reuters Health) - Drugs called dopamine agonists, used to treat Parkinson's disease, may trigger sudden uncontrollable somnolence in about one in five patients.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.